GLPwatch
Vomiting
31,671 FAERS reports across 13 drugs
Last updated 2026-08-26 06:04 UTCVomiting is the forceful expulsion of the contents of the stomach through the mouth.
Plain-language definition of the term.
Vomiting is listed as an adverse reaction in the FDA labels for multiple GLP-1 drugs, including Byetta, Mounjaro, Ozempic, Rybelsus, Saxenda, Soliqua, Trulicity, Victoza, Wegovy, Xultophy, and Zepbound.
AI summary of the sources below.
FAERS report counts (as of 2026Q2) reflect voluntary adverse-event reports and cannot establish causation or true frequency; higher counts often track prescription volume. openFDA FAERS ↗
Reports by drug
| Drug | FAERS reports | Quarter |
|---|---|---|
| Ozempic | 6,341 | 2026Q2 |
| Trulicity | 5,657 | 2026Q2 |
| Mounjaro | 4,805 | 2026Q2 |
| Byetta | 4,326 | 2026Q2 |
| Zepbound | 3,180 | 2026Q2 |
| Victoza | 2,886 | 2026Q2 |
| Wegovy | 1,839 | 2026Q2 |
| Bydureon | 1,118 | 2026Q2 |
| Rybelsus | 737 | 2026Q2 |
| Saxenda | 617 | 2026Q2 |
| Xultophy | 87 | 2026Q2 |
| Soliqua | 77 | 2026Q2 |
| Adlyxin | 1 | 2026Q2 |
Mentioned in FDA labels
Research mentioning vomiting (7)
- Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
- Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects.
- Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.
- Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies.
- Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide.
- Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.